Dendritic cell vaccines for high-grade gliomas

References

• LouisDNOhgakiHWiestlerODThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol200711429710917618441
   PubMed Web of Science ®Google Scholar
• OstromQTGittlemanHFulopJCBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012Neuro Oncol201517Suppl 4iv1iv6226511214
   PubMed Web of Science ®Google Scholar
• DarlixAZouaouiSRigauVEpidemiology for primary brain tumors: a nationwide population-based studyJ Neuro Oncol20171313525546
   Web of Science ®Google Scholar
• WellerMvan den BentMHopkinsKEANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastomaLancet Oncol2014159E395E40325079102
   PubMed Web of Science ®Google Scholar
• WenPYKesariSMalignant gliomas in adultsN Engl J Med2008359549250718669428
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJEuropean Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials GroupRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• BadhiwalaJDeckerWKBerensMEBhardwajRDClinical trials in cellular immunotherapy for brain/CNS tumorsExpert Rev Neurother201313440542423545055
   PubMed Web of Science ®Google Scholar
• ThonNKrethSKrethFWPersonalized treatment strategies in glioblastoma: MGMT promoter methylation statusOnco Targets Ther201361363137224109190
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• EstellerMGarcia-FoncillasJAndionEInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agentsN Engl J Med2000343191350135411070098
   PubMed Web of Science ®Google Scholar
• BelkaCBudachWKortmannRDBambergMRadiation induced CNS toxicity – molecular and cellular mechanismsBr J Cancer20018591233123911720454
   PubMed Web of Science ®Google Scholar
• MonjeMLPalmerTRadiation injury and neurogenesisCurr Opin Neurol200316212913412644738
   PubMed Web of Science ®Google Scholar
• PolivkaJJrPolivkaJHolubecLAdvances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiformeAnticancer Res2017371213328011470
   PubMed Web of Science ®Google Scholar
• WangGFuXLWangJJGuanRTangXJNovel strategies to discover effective drug targets in metabolic and immune therapy for glioblastomaCurr Cancer Drug Targets2017171173927562399
   PubMed Web of Science ®Google Scholar
• ClarkeJButowskiNChangSRecent advances in therapy for glioblastomaArch Neurol201067327928320212224
   PubMedGoogle Scholar
• KimREmiMTanabeKCancer immunoediting from immune surveillance to immune escapeImmunology2007121111417386080
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• PaluckaKBanchereauJCancer immunotherapy via dendritic cellsNat Rev Cancer201212426527722437871
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• RestifoNPDudleyMERosenbergSAAdoptive immunotherapy for cancer: harnessing the T cell responseNat Rev Immunol201212426928122437939
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCRestifoNPCancer immunotherapy: moving beyond current vaccinesNat Med200410990991515340416
   PubMed Web of Science ®Google Scholar
• NittaTHishiiMSatoKOkumuraKSelective expression of interleukin-10 gene within glioblastoma-multiformeBrain Res19946491–21221287953624
   PubMed Web of Science ®Google Scholar
• SawamuraYDiserensACde TriboletNIn vitro prostaglandin-E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytesJ Neuro Oncol199092125130
   Web of Science ®Google Scholar
• CouldwellWTYongVWDore DuffyPFreedmanMSAntelJPProduction of soluble autocrine inhibitory factors by human glioma cell-linesJ Neurol Sci19921101–21781851506857
   PubMed Web of Science ®Google Scholar
• YangBCLinHKHorWSMediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathwayJ Immunol200317183947395414530312
   PubMed Web of Science ®Google Scholar
• RoriveSBelotNDecaesteckerCGalectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchymaGlia200133324125511241742
   PubMed Web of Science ®Google Scholar
• ParsaATWaldronJSPannerALoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNat Med2007131848817159987
   PubMed Web of Science ®Google Scholar
• FacoettiANanoRZeliniPHuman leukocyte antigen and antigen processing machinery component defects in astrocytic tumorsClin Cancer Res200511238304831116322289
   PubMed Web of Science ®Google Scholar
• FecciPEMitchellDAWhitesidesJFIncreased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaCancer Res20066663294330216540683
   PubMed Web of Science ®Google Scholar
• El AndaloussiALesniakMSAn increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiformeNeuro Oncol20068323424316723631
   PubMed Web of Science ®Google Scholar
• JacobsJFIdemaAJBolKFRegulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumorsNeuro Oncol200911439440219028999
   PubMed Web of Science ®Google Scholar
• GustafsonMPLinYNewKCSystemic immune suppression in glioblastoma: the interplay between CD14(+)HLA-DRlo/neg monocytes, tumor factors, and dexamethasoneNeuro Oncol201012763164420179016
   PubMed Web of Science ®Google Scholar
• BenenciaFSpragueLMcGintyJPateMMuccioliMDendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccinationJ Biomed Biotechnol2012201242547622505809
   PubMedGoogle Scholar
• SchallerTHSampsonJHAdvances and challenges: dendritic cell vaccination strategies for glioblastomaExpert Rev Vaccines2017161273627500911
   PubMed Web of Science ®Google Scholar
• AshleyDMFaiolaBNairSHaleLPBignerDDGilboaEBone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumorsJ Exp Med19971867117711829314567
   PubMed Web of Science ®Google Scholar
• FuertesMBKachaAKKlineJHost type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cellsJ Exp Med2011208102005201621930765
   PubMed Web of Science ®Google Scholar
• DiamondMSKinderMMatsushitaHType I interferon is selectively required by dendritic cells for immune rejection of tumorsJ Exp Med2011208101989200321930769
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDIMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• DillmanROCancer immunotherapyCancer Biother Radiopharm201126116421355777
   PubMed Web of Science ®Google Scholar
• KikuchiTAkasakiYIrieMHommaSAbeTOhnoTResults of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cellsCancer Immunol Immunother200150733734411676393
   PubMed Web of Science ®Google Scholar
• YuJSWheelerCJZeltzerPMVaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltrationCancer Res200161384284711221866
   PubMed Web of Science ®Google Scholar
• YamanakaRAbeTYajimaNVaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trialBr J Cancer20038971172117914520441
   PubMed Web of Science ®Google Scholar
• CarusoDAOrmeLMNealeAMResults of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancerNeuro Oncol20046323624615279716
   PubMed Web of Science ®Google Scholar
• KikuchiTAkasakiYAbeTVaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12J Immunother200427645245915534489
   PubMed Web of Science ®Google Scholar
• RutkowskiSDe VleeschouwerSKaempgenESurgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility studyBr J Cancer20049191656166215477864
   PubMed Web of Science ®Google Scholar
• YuJSLiuGTYingHYongWHBlackKLWheelerCJVaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant gliomaCancer Res200464144973497915256471
   PubMed Web of Science ®Google Scholar
• LiauLMPrinsRMKiertscherSMDendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironmentClin Cancer Res200511155515552516061868
   PubMed Web of Science ®Google Scholar
• YamanakaRHommaJYajimaNClinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trialClin Cancer Res200511114160416715930352
   PubMed Web of Science ®Google Scholar
• OkadaHLiebermanFSWalterKAAutologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasJ Transl Med200756718093335
   PubMed Web of Science ®Google Scholar
• De VleeschouwerSFieuwsSRutkowskiSPostoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiformeClin Cancer Res200814103098310418483377
   PubMed Web of Science ®Google Scholar
• WalkerDGLahertyRTomlinsonFHChuahTSchmidtCResults of a Phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapyJ Clin Neurosci200815211412118083572
   PubMed Web of Science ®Google Scholar
• WheelerCJBlackKLLiuGTVaccination elicits correlated immune and clinical responses in glioblastoma multiforme patientsCancer Res200868145955596418632651
   PubMed Web of Science ®Google Scholar
• SampsonJHArcherGEMitchellDAAn epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeMol Cancer Ther20098102773277919825799
   PubMed Web of Science ®Google Scholar
• ArdonHDe VleeschouwerSVan CalenberghFAdjuvant dendritic cell-based tumour vaccination for children with malignant brain tumoursPediatr Blood Cancer201054451952519852061
   PubMed Web of Science ®Google Scholar
• ArdonHVan GoolSLopesISIntegration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot studyJ Neuro Oncol2010992261272
   PubMed Web of Science ®Google Scholar
• ChangCNHuangYCYangDMA Phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant gliomaJ Clin Neurosci20111881048105421715171
   PubMed Web of Science ®Google Scholar
• FadulCEFisherJLHamptonTHImmune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapyJ Immunother201134438238921499132
   PubMed Web of Science ®Google Scholar
• OkadaHKalinskiPUedaRInduction of CD8(+) T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaJ Clin Oncol201129333033621149657
   PubMed Web of Science ®Google Scholar
• PrinsRMSotoHKonkankitVGene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapyClin Cancer Res20111761603161521135147
   PubMed Web of Science ®Google Scholar
• AkiyamaYOshitaCKumeAα-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trialBMC Cancer20121262323270484
   PubMed Web of Science ®Google Scholar
• ArdonHVan GoolSWVerschuereTIntegration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trialCancer Immunol Immunother201261112033204422527250
   PubMed Web of Science ®Google Scholar
• ChoDYYangWKLeeHCAdjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trialWorld Neurosurg2012775–673674422120301
   PubMed Web of Science ®Google Scholar
• JieXHuaLJiangWFengFFengGHuaZClinical application of a dendritic cell vaccine raised against heat-shocked glioblastomaCell Biochem Biophys2012621919921909820
   PubMed Web of Science ®Google Scholar
• LaskyJL3rdPanosyanEHPlantAAutologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomasAnticancer Res20133352047205623645755
   PubMed Web of Science ®Google Scholar
• PhuphanichSWheelerCJRudnickJDPhase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunol Immunother201362112513522847020
   PubMed Web of Science ®Google Scholar
• PrinsRMWangXYSotoHComparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patientsJ Immunother201336215215723377664
   PubMed Web of Science ®Google Scholar
• Vik-MoEONyakasMMikkelsenBVTherapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaCancer Immunol Immunother20136291499150923817721
   PubMed Web of Science ®Google Scholar
• HunnMKBauerEWoodCEDendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiformeJ Neuro Oncol20151212319329
   PubMed Web of Science ®Google Scholar
• MitchellDABatichKAGunnMDTetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patientsNature2015519754336636925762141
   PubMed Web of Science ®Google Scholar
• SakaiKShimodairaSMaejimaSDendritic cell-based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant gliomaJ Neurosurg2015123498999726252465
   PubMed Web of Science ®Google Scholar
• BatichKAReapEAArcherGELong-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccinationClin Cancer Res20172381898190928411277
   PubMed Web of Science ®Google Scholar
• InogésSTejadaSde CerioALA phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patientsJ Transl Med201715110428499389
   PubMed Web of Science ®Google Scholar
• GargADVara PerezMSchaafMTrial watch: dendritic cell-based anticancer immunotherapyOncoimmunology201767e132834128811970
   PubMed Web of Science ®Google Scholar
• HovdenAOAppelSThe first dendritic cell-based therapeutic cancer vaccine is approved by the FDAScand J Immunol201072655421044130
   PubMed Web of Science ®Google Scholar
• WolffJEDäumlingEDirksenADabrockAHartmannMJürgensHMunster Heidelberg Abilities Scale – a measuring instrument for global comparison of illness sequelaeKlin Padiatr19962085294298 Article in German8992097
   PubMed Web of Science ®Google Scholar
• AaronsonNKAhmedzaiSBergmanBThe European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst19938553653768433390
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRKEYNOTE-001 InvestigatorsPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• RamadanGGeneration of functional monocyte-derived fast dendritic cells suitable for clinical application in the absence of interleukin-6Cytotechnology201163551352121766179
   PubMed Web of Science ®Google Scholar
• KvistborgPBoeghMPedersenAWClaessonMHZoccaMBFast generation of dendritic cellsCell Immunol20092601566219818956
   PubMed Web of Science ®Google Scholar
• De VriesIJKrooshoopDJScharenborgNMEffective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation stateCancer Res2003631121712517769
   PubMed Web of Science ®Google Scholar
• RadfordKJTullettKMLahoudMHDendritic cells and cancer immunotherapyCurr Opin Immunol201427263224513968
   PubMed Web of Science ®Google Scholar
• MahnkeKQianYFondelSBrueckJBeckerCEnkAHTargeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in miceCancer Res200565157007701216061687
   PubMed Web of Science ®Google Scholar
• DhodapkarMVSznolMZhaoBInduction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205Sci Transl Med20146232232ra251
   Web of Science ®Google Scholar